Mundipharma expands its regional footprint with strong participation at DUPHAT

March 15, 2016 - 6 minutes read

Mundipharma’s latest products showcased at DUPHAT

Dubai, U.A.E, 15th March 2016 – Mundipharma, a pharmaceutical leader in pain management, participated with a much stronger presence at the 2016 Dubai International Pharmaceutical and technologies (DUPHAT) conference.

At the exhibition, Mundipharma displayed their complete pain management portfolio, their consumer health line with BETADINE®, as well as their specialty care medicines for the management of asthma. In addition to the extensive portfolio, Mundipharma recently expanded their offerings with the acquisition of MSD’s Ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension.

Speaking at the exhibition & conference, Dr. Ashraf Allam, Regional Vice President of Mundipharma Middle East and Africa region commented, “We are proud to be participating at DUPHAT with an even stronger presence this year. The conference is an excellent opportunity for us to connect with thousands of pharmacists, physicians, scientists, paramedical professionals & trade visitors from across the region. We’ve been extremely nimble and entrepreneurial in our approach, which has won us considerable success. This provision of Ophthalmology is a key milestone in strengthening Mundipharma’s footprint and ongoing investment in specialty care medicines. With our expanded portfolio, pharmacists and physicians can offer patients an even wider range of treatment solutions to meet their

Mundipharma is also focused on building a presence in respiratory disease, particularly in bronchial asthma, a condition that affects millions of people worldwide.

The flagship brand, BETADINE® (Povidone Iodine) antiseptic range is one of Mundipharma’s most well-known products that is not only trusted by hospitals worldwide, but is also rated Super Brand in the UAE for the second connective year. BETADINE® has repeatedly demonstrated proven effectiveness against a diverse range of pathogens including the Ebola 1 virus, and has kept generations of families protected from infections.

“BETADINE® is an important first line of defence against topical infections,” Allam explained. “It is a trusted brand among consumers at home, to treat small wounds and grazes, sore throats, feminine infections, and to stop minor problems from escalating. Povidone-iodine, the key active ingredient of BETADINE®, kills a broad range of bacteria, viruses and fungi, including antibiotic resistant strains 2, 3 & 4 as well as some of the most recent lethal viruses such as SARS 5, MERS 6, and the Ebola 1.”

Mundipharma’s analgesic portfolio focuses on the treatment of acute and chronic pain, of moderate to severe intensity, caused by cancer and other non-malignant conditions. The Mundipharma pain arsenal includes immediate and controlled-release tablets, and various other formulations, such as capsules, injections and patches, suited to the different needs of individual patients. The existing range of oncology products includes treatments for neuro-oncological, rare haematological malignancies and cancer supportive care.

“We are proud of our complete portfolio of speciality medicines that are known to treat a number of serious healthcare issues. Our mission and commitment is to improve the health and quality of life by continuing to provide a wide range of best-in-class treatment solutions,”

The company is exhibiting at DUPHAT 2016 in Sheikh Rashid Hall, Dubai International Convention and Exhibition Centre.

-END –

About Mundipharma

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory, consumer healthcare and rheumatoid arthritis.

For Media Inquiries (Not for publishing)
Shamim Kassibawi, Spread Communications, +971 50 550 3230, Shamim@spreadcomms.com

Mundipharma Middle East and Africa Region
Patrycja Czoch, Corporate Communications Manager
Mobile: +971508512700, Patrycja.Czoch@mundipharma.ae

®: BETADINE is a registered trademark of Mundipharma

References

1 – Eggers et al. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infectious Diseases (2015) 15:375.
2-Sibbald RG, Leaoer DJ, Queen D. Iodine Made Easy. Wounds International 2011; 2(2): Available from http://www.woundsinternational.com.
3-Lachapelle J-M et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin. Pract. 2013; 10(5): 579–592.
4-Fleisher W. Povidone-iodine in Antisepsis –State of the Art. Dermatology 1997;195(suppl 2):3-
5 – Kariwa H, et al. Inactivation of SARS Coronavirus by Means of Povidone-Iodine, Physical Conditions and Chemical Reagents. Dermatology 2006;212(suppl 1):119-123.
6 – Eggers M et al. Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA).

Infect Dis Ther. 2015 Sep 28. [Epub ahead of print]. DOI 10.1007/s40121-015-0091-9.